


Acapella™ Respiratory Therapy System Nebuliser Placement

This white paper was developed based on a review of the articles referenced below.



The treatment of chronic lung diseases typically includes the use of a nebuliser to deliver medication. Aerosolised drugs can include antibiotics, corticosteroids, and saline, and these medications can help with, among other things, secretion hydration. However, the use of a nebuliser can also add time to daily therapies. Therefore, combining a nebuliser with the Acapella respiratory therapy system can reduce the total time of therapy and may help with secretion removal due to hydration.¹ Clinicians now have the option to place the nebuliser between the mouthpiece and the device. Aerosol lung deposition with the placement of the nebuliser in this position has been shown to be similar to a nebuliser alone.² This new placement may improve confidence that patients are receiving the appropriate dosage of nebulised medication and still obtaining the benefits of oscillatory positive expiratory pressure (PEP).

The Acapella respiratory therapy system combines high-frequency oscillations and PEP into a single treatment. Exhaled air is opposed as it passes through the device, resulting in PEP. Additionally, this expired flow is intermittently occluded by a moving magnetic counterweight, producing air flow oscillations. The use of a magnetic counterweight allows for non-position dependent usage of the device and still allows for a patient-specific therapy by adjusting the magnet positioning. There are 20 resistance settings on the Acapella respiratory therapy system, allowing for optimisation of frequency, oscillation amplitude, and mean pressure. The Acapella respiratory therapy system family of products— Acapella Choice™ blue, DH (green) and DM (blue)—has been shown to reach a range of PEP (3–23 cm H₂O) and frequency of oscillation (8.5–21 Hz).^{2,3,4,5,6,7}



Proximal placement of a nebuliser on the Acapella respiratory therapy system. Items shown above are standard use for our device and not sold by ICU Medical.

References

1. Fink JB. Humidity and aerosol therapy, Cairo JM, Pilbeam SP. Mosby's Respiratory Care Equipment, 8th edition. St Louis: Mosby;2009:150-204
2. Mesquita FO et al. Scintigraphic assessment of radio-aerosol pulmonary deposition with the Acapella positive expiratory pressure device and various nebulizer configurations. *Respir Care*. 2014;59(3):328-33
3. Alves CE, Nunes LGMQ, Melo PL. Mechanical analysis of an oscillatory positive expiratory pressure device used in respiratory rehabilitation. *Annu Int Conf IEEE Eng Med Biol Soc*. 2010;2010:2477-80
4. Silva CEA, Santos JG, Jansen JM, de Melo PL. Laboratory evaluation of the Acapella device: pressure characteristics under different conditions, and a software tool to optimize its practical use. *Respir Care* 2009;54(11):1480-1487
5. Mueller G et al. Laboratory evaluation of four different devices for secretion mobilization: Acapella choice, green, blue versus water bottle. *Respir Care* 2014;59(5):673-677
6. Dos Santos AP, Guimaraes RC, de Carvalho EM, Gastaldi AC. Mechanical behaviors of Flutter VRP1, shaker, and Acapella devices. *Respir Care* 2013 Feb;58(2):298-304
7. Volsko TA, DiFiore J, Chatburn RL. Performance comparison of two oscillating positive expiratory pressure devices: Acapella versus Flutter. *Respir Care*. 2003 Feb;48(2):124-30